Stocktoria
IN8BIO, INC. INAB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-12
IN8BIO, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $10.2M | $17.0M | $16.8M | $14.1M | $7.3M |
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| EPS (diluted) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 |
| Operating cash flow | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M |
| Shareholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | -$38.2M |
Source: SEC EDGAR filings · CIK 0001740279 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.